BDP1 and ovarian serous adenocarcinoma: At twelve‐month relapse‐free survival, in patients treated with taxane, BDP1 expression significantly decreased (p = 0.0059), and the ROC analysis (p = 8.4 × 10−04, AUC = 0.654) (Figure 5B) suggest BDP1 may be of predictive value in patients with serous ovarian cancer.